Related Experiment Video
Updated: May 19, 2026
In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
Recombinant human decorin suppresses liver HepG2 carcinoma cells by p21 upregulation
Yucheng Zhang1, Yali Wang, Zhenwu Du
1Central Laboratory, China-Japan Union Hospital, Jilin University, Changchun, People's Republic of China.
Background:
Decorin is a multifunctional molecule of the extracellular matrix and impedes different kinds of tumor cell growth, but the role and molecular mechanism by which decorin inhibits HepG2 cells is not fully understood. Our objective was to construct recombinant human decorin (pcDNA3.1-DCN) and to explore the mechanism by which it inhibits HepG2 cells.
Methods:
This experiment was divided into three groups, ie, a control group, an empty vector group, and a pcDNA3.1-DCN group. pcDNA3.1-DCN was constructed using recombinant DNA technology, and the vector for pcDNA3.1-DCN and pcDNA3.1 was then transfected into HepG2 cells using Lipofectamine 2000.
Results:
Compared with cells in the control group and in the empty vector group, growth of cells in the pcDNA3.1-DCN group was significantly suppressed, the ratios of cells in the G0/G1 phases and proportion of early apoptotic cells were significantly increased, and the level of p21(WAF1/CIP1) (p21) protein was markedly upregulated (P < 0.05). However, there was no significant difference among the three groups in p53 protein expression (P > 0.05).
Conclusion:
The pcDNA3.1-DCN vector was successfully constructed and transfected into HepG2 cells, and decorin overexpression suppressed the growth of HepG2 cells by upregulation of p21 via a p53-independent pathway.
Insights
Decorin (DCN) gene therapy suppressed HepG2 liver cancer cell growth by increasing cell cycle arrest and apoptosis. This occurred through p21 protein upregulation, independent of p53.
Area of Science:
- Molecular Biology
- Cancer Research
- Biochemistry
Background:
- Decorin (DCN) is an extracellular matrix molecule with known anti-tumor properties.
- The precise mechanisms by which decorin inhibits HepG2 liver cancer cells remain unclear.
- This study aimed to investigate decorin's inhibitory role and molecular pathways in HepG2 cells.
Purpose of the Study:
- To construct a recombinant human decorin expression vector (pcDNA3.1-DCN).
- To explore the molecular mechanisms underlying decorin's inhibition of HepG2 cell proliferation.
- To elucidate the role of decorin in regulating cell cycle and apoptosis in HepG2 cells.
Main Methods:
- Recombinant DNA technology was used to construct the pcDNA3.1-DCN vector.
- HepG2 cells were divided into control, empty vector, and pcDNA3.1-DCN groups.
- Lipofectamine 2000 was employed for the transfection of vectors into HepG2 cells.
Main Results:
- Overexpression of decorin in HepG2 cells significantly suppressed cell growth compared to control and empty vector groups.
- Decorin treatment led to a significant increase in G0/G1 cell cycle phase arrest and early apoptosis.
- The level of p21(WAF1/CIP1) (p21) protein was markedly upregulated in cells with decorin overexpression.
- No significant difference in p53 protein expression was observed among the groups.
Conclusions:
- Successful construction and transfection of the pcDNA3.1-DCN vector were achieved.
- Decorin overexpression effectively suppressed HepG2 cell growth.
- The growth inhibition is mediated by the upregulation of p21 protein through a p53-independent pathway.
